Vaxcyte narrows timing for pivotal VAX-31 data to late October (PCVX:NASDAQ)
· seekingalpha.com
Vaxcyte (PCVX) narrows OPUS-1 Phase 3 VAX-31 vaccine results to end-Oct, a key catalyst vs Pfizer Prevnar.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...